TXNL4B

Across TCGA pan-cancer cohorts, TXNL4B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TXNL4B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TXNL4B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TXNL4B is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC, LSCC, and COAD are the cancer types where TXNL4B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TXNL4B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.408	<.001	11	view →
LSCC	All	II,III,IV	+0.202	.001	7	view →
COAD	All	III,IV	−0.898	.002	6	view →
LUAD	Male	All	+0.281	<.001	6	view →
HNSC	Male	III,IV	+0.205	<.001	6	view →
PDAC	Female	III,IV	+1.110	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TXNL4B–CCRCC

Open the CCRCC breakdown →